Personalized medicine in CLL: current status and future perspectives.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Letters

• Publication date

  2014-09-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.canlet.2013.07.013PMID 23879961PMCID PMC3871981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.

  2016cited by this paper
• High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations

  2014cited by this paper
• The significance of spliceosome mutations in chronic lymphocytic leukemia

  2013cited by this paper
• Deletion 11q Abnormality in Patients With Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (Clinical and Radiological) at Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients With CLL and del11q Cytogenetic Abnormality

  2013cited by this paper
• Molecular Oncology: B-cell chronic lymphocytic leukemia

  2013cited by this paper
• Geography, ethnicity and “roots” in chronic lymphocytic leukemia

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Is Chronic Lymphocytic Leukemia Still Incurable

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia

  2012cited by this paper
• A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

  2012cited by this paper
• High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

  2012cited by this paper
• Low dose palliative radiotherapy for splenomegaly in hematologic disorders

  2012cited by this paper
• Hematologist/oncologist disease‐specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

  2012cited by this paper
• A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

  2012cited by this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cited by this paper
• Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine

  2012cited by this paper
• Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

  2012cited by this paper
• ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

  2012cited by this paper
• Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

  2012cited by this paper
• Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia.

  2012cited by this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cited by this paper
• Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

  2012cited by this paper
• Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

  2012cited by this paper
• Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

  2011cited by this paper
• Chronic lymphocytic leukemia in less fit patients: “slow-go”

  2011cited by this paper
• Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

  2011cited by this paper
• Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

  2011cited by this paper
• Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

  2011cited by this paper
• SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

  2011cited by this paper
• A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

  2011cited by this paper
• Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia

  2011cited by this paper
• Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

  2011cited by this paper
• Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

  2011cited by this paper
• What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?

  2011cited by this paper
• Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.

  2011cited by this paper
• Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010influential reference
• Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia

  2010cited by this paper
• Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.

  2010cited by this paper
• Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia

  2010cited by this paper
• The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines

  2010cited by this paper
• The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

  2010cited by this paper
• CNS Disease In Younger Patients (

  2010cited by this paper
• TP53 mutation and survival in chronic lymphocytic leukemia.

  2010cited by this paper
• microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification.

  2009cited by this paper
• Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

  2009cited by this paper
• State-of-the-art treatment of chronic lymphocytic leukemia.

  2009cited by this paper
• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

  2009cited by this paper
• The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

  2009cited by this paper
• Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

  2009cited by this paper
• Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

  2009cited by this paper
• 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

  2009cited by this paper
• Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.

  2009cited by this paper
• Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL

  2009cited by this paper
• Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

  2008cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

  2008cited by this paper
• Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.

  2008influential reference
• Lenalidomide for the treatment of B-cell malignancies.

  2008cited by this paper
• Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis

  2008cited by this paper
• Low‐dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

  2008cited by this paper
• A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

  2008cited by this paper
• Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

  2008cited by this paper
• Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.

  2008cited by this paper
• Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus

  2007cited by this paper
• Oblimersen for the treatment of patients with chronic lymphocytic leukemia

  2007cited by this paper
• Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

  2007cited by this paper
• Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

  2007cited by this paper
• Alemtuzumab in chronic lymphocytic leukemia

  2007cited by this paper
• Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

  2007cited by this paper
• Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

  2007cited by this paper
• Graft-versus-leukemia in chronic lymphocytic leukemia

  2007cited by this paper
• Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

  2007cited by this paper
• Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.

  2007cited by this paper
• Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

  2007cited by this paper
• Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

  2006cited by this paper
• How I treat refractory CLL.

  2006cited by this paper
• Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.

  2005cited by this paper
• Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

  2005cited by this paper
• A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

  2005influential reference
• Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

  2005cited by this paper
• Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

  2005cited by this paper
• Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• Bryostatin Induces Protein Kinase C Modulation, Mcl-1 Up-Regulation and Phosphorylation of Bcl-2 Resulting in Cellular Differentiation and Resistance to Drug-induced Apoptosis in B-cell Chronic Lymphocytic Leukemia Cells

  2004cited by this paper
• MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.

  2004cited by this paper
• Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets

  2004cited by this paper
• Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

  2003cited by this paper
• ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

  2003influential reference
• High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

  2003cited by this paper
• Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

  2002cited by this paper

• Favorable outcomes of restrictive treatment indications in chronic lymphocytic leukemia: a retrospective analysis of Brazilian Registry of CLL

  2025cites this paper
• Association of Cytogenetics Aberrations and IGHV Mutations with Outcome in Chronic Lymphocytic Leukemia Patients in a Real-World Clinical Setting

  2024cites this paper
• Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies

  2024cites this paper
• Research progress on gene mutations and drug resistance in leukemia.

  2024cites this paper
• Multifunctional Ag-decorated core-shell heterojunction of red phosphorus/silicon carbide nanowires for highly sensitive SERS-based monitoring of ibrutinib

  2024cites this paper
• A personalized stepwise dynamic predictive algorithm of the time to first treatment in chronic lymphocytic leukemia

  2023influential citation
• Chronic Lymphoid Leukemia: a systematic review of its epidemiological, etiological and genetic aspects

  2023cites this paper
• Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region

  2023cites this paper
• Formation of ibrutinib solvates: so similar, yet so different

  2023cites this paper
• Babesia microti-induced fulminant sepsis in an immunocompromised host: A case report and the case-specific literature review

  2022cites this paper
• STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells

  2022cites this paper
• Artificial Intelligence in Personalized Medicine

  2021cites this paper
• Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3

  2021cites this paper
• Diverse Cancer Therapeutic Interactions: Complexities in Cancer Management

  2020cites this paper
• Leucemia linfoide crónica de células B: revisión de sus aspectos etiopatogénicos, moleculares y pronósticos

  2019cites this paper
• STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo

  2019cites this paper
• Silencing Notch-1 enhances fludarabine chemosensitivity in chronic lymphocytic leukemia

  2019cites this paper
• The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL)

  2019cites this paper
• Systematic tracking of altered modules identifies the key biomarkers involved in chronic lymphocytic leukemia

  2018cites this paper
• Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?

  2018cites this paper
• Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia

  2018cites this paper
• ROR1 as a target for cancer immunotherapy

  2017cites this paper
• Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia

  2017cites this paper
• First Crystal Structures of Pharmaceutical Ibrutinib: Systematic Solvate Screening and Characterization

  2017cites this paper
• New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia

  2017cites this paper
• Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH.

  2017cites this paper
• The relationship between the polymorphism (rs6449182) of CD38 and the prognosis of patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide and rituximab (FCR): a 4 year prospective cohort study

  2016influential citation
• Plumbagin reduces chronic lymphocytic leukemia cell survival by downregulation of Bcl-2 but upregulation of the Bax protein level.

  2016cites this paper
• Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations.

  2016cites this paper
• A Translational Bioinformatics Approach to Parsing and Mapping ISCN Karyotypes: A Computational Cytogenetic Analysis of Chronic Lymphocytic Leukemia (CLL)

  2016cites this paper
• Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self‐nanoemulsifying drug delivery system

  2016cites this paper
• Present and future of personalized medicine in CLL.

  2016cites this paper
• Thermodynamics of solubility of ibrutinib in ethanol + water cosolvent mixtures at different temperatures

  2015cites this paper
• Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

  2015cites this paper
• UNIVERSITY OF CALIFORNIA, SAN DIEGO Identification of Mutations in Chronic Lymphocytic Leukemia using ccf-DNA Isolated by Dielectrophoresis A thesis submitted in partial satisfaction of the requirements for the degree Master of Science in Bioengineering

  2015cites this paper
• The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.

  2015cites this paper
• Solubility and thermodynamic function of a new anticancer drug ibrutinib in 2-(2-ethoxyethoxy)ethanol + water mixtures at different temperatures

  2015cites this paper
• Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia

  2014cites this paper
• Exploring the iceberg of Chronic Lymphocytic Leukaemia

  2014cites this paper
• Precision medicine--delivering the goods?

  2014cites this paper
• Leucemialinfocíticacrónica delinfocitosB:unmodelo personalizado de valoración clínicaymolecular

  2014cites this paper